A 38-year-old woman presents with progressive central obesity, proximal muscle weakness, and purple striae. Investigations reveal elevated 24-hour urinary free cortisol and loss of normal diurnal cortisol rhythm. CT abdomen shows a 2.5 cm adrenal adenoma. After confirming ACTH-independent Cushing syndrome, what is the drug of choice for medical management if surgery is contraindicated or refused?

Explanation

## Medical Management of ACTH-Independent Cushing Syndrome (Benign Adrenal Adenoma) ### Drug of Choice: Ketoconazole **Key Point:** For ACTH-independent Cushing syndrome due to a **benign adrenal adenoma**, when surgery is contraindicated or refused, **ketoconazole** is the preferred first-line medical agent for long-term cortisol suppression (Harrison's Principles of Internal Medicine, 21st ed.). **High-Yield:** Ketoconazole inhibits multiple cytochrome P450 enzymes in the steroidogenesis pathway (CYP11A1/side-chain cleavage, CYP17α, CYP11B1), effectively reducing cortisol synthesis at several steps. It has an intermediate onset (hours to days) and is reversible, making it safe and titratable for chronic use in benign disease. ### Why NOT Mitotane Here? - Mitotane is an **adrenolytic** agent that causes **irreversible destruction** of adrenocortical cells. - Its primary indication is **adrenocortical carcinoma (ACC)** — not benign adenoma. - Using an irreversible adrenolytic in benign disease carries unacceptable risk of permanent adrenal insufficiency without oncologic benefit. - Mitotane requires therapeutic drug monitoring (target 14–20 mg/L) and has a slow onset (weeks to months), making it unsuitable as first-line for benign adenoma. ### Comparison of Adrenal-Suppressing Agents | Agent | Mechanism | Onset | Reversibility | Primary Indication | |-------|-----------|-------|----------------|--------------------| | **Ketoconazole** | CYP11A1/17α/11B1 inhibitor | Hours–days | Reversible | **First-line for benign Cushing (surgery refused)** | | Metyrapone | 11β-hydroxylase inhibitor | Hours | Reversible | Second-line; rapid control | | Mitotane | Adrenolytic | Weeks–months | Irreversible | Adrenocortical carcinoma | | Etomidate | CYP11A1 inhibitor (IV) | Minutes | Reversible | ICU emergency only | ### Clinical Scenario Fit - **2.5 cm adrenal adenoma** → benign ACTH-independent Cushing - **Surgery contraindicated/refused** → long-term medical therapy needed - **Ketoconazole** is the standard first-line choice: effective, reversible, orally administered, and well-studied in benign adrenal Cushing syndrome **Clinical Pearl:** Monitor liver function tests during ketoconazole therapy due to hepatotoxicity risk. Metyrapone is an acceptable alternative, particularly when rapid cortisol control is needed or ketoconazole is not tolerated. **High-Yield:** Mitotane = adrenocortical **carcinoma**; Ketoconazole = benign adrenal adenoma with surgery refused. This distinction is frequently tested in NEET PG / INI-CET.